Strategic partnerships Leverage Clarapath's demonstrated investor and strategic backing (Northwell Ventures, Mayo Clinic, Ochsner Ventures) and recent acquisitions to pursue co-development, integration with major pathology networks, and joint commercialization opportunities that expand market reach.

Robotics portfolio expansion Target health systems and pathology laboratories seeking automated tissue sectioning by highlighting ongoing product evolution with SectionStar and TrimStar Pro launches, emphasizing throughput gains, standardization, and digital transformation benefits.

Expansion-ready status Position the company’s growth signals and Series B financing history as proof points for scale; approach large regional labs and academic centers that value validated robotics platforms and upcoming product roadmaps.

Technology stack leverage Offer integration opportunities with existing lab IT, data analytics, and LIMS workflows by aligning with Clarapath’s tech stack (PostgreSQL, MongoDB, Splunk, Ubuntu) to enable seamless data capture, monitoring, and security across pathology operations.

Global market potential Emphasize the addressable market for automated microtomy across hospitals, research institutes, and veterinary pathology; propose pilots or regional deployments that demonstrate cost savings, reduced labor delays, and quality improvements to secure broad adoption.